文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

瑞马唑仑与咪达唑仑用于诊断性上消化道内镜镇静的随机对照试验研究方案

Remimazolam versus midazolam for sedation in diagnostic upper gastrointestinal endoscopy: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2026-04-11

本研究为随机对照多中心试验,旨在比较瑞马唑仑与咪达唑仑在诊断性上消化道内镜镇静中的有效性和安全性。受试者按1:1随机分组,主要终点为总操作时间(从首次给药至离院),次要终点包括镇静成功率、恢复时间及不良事件发生率等。

要点

  • 瑞马唑仑组初始5 mg,可追加2.5 mg,最多5次;咪达唑仑组初始2 mg,追加1~2 mg,最多5次。
  • 主要终点为总操作时间,即从首次给予镇静药至离院的时间。
  • 次要终点包括镇静成功率、恢复时间、诱导时间、不良事件及患者满意度等。

核心结论

  • 该试验结果预期证明瑞马唑仑具有更优的有效性和良好的安全性,可能优先用于诊断性上消化道内镜镇静。

研究设计与样本

  • 随机、对照、多中心试验,受试者为接受诊断性上消化道内镜的患者,按1:1随机分配至瑞马唑仑组或咪达唑仑组。

关键数值与推荐

  • 瑞马唑仑组给药方案:初始5 mg,追加2.5 mg,最多追加5次。
  • 咪达唑仑组给药方案:初始2 mg,追加1~2 mg,最多追加5次。
  • 主要终点为总操作时间,定义为从首次给予镇静药至离院的时间。
  • 次要终点包括镇静成功率、恢复时间、诱导时间、总内镜时间、离院时间、镇静时间、低血压、呼吸抑制、心动过速、心动过缓发生率、患者满意度及矛盾反应发生率。

临床怎么用

  • 若试验达到预期,瑞马唑仑可作为诊断性上消化道内镜镇静的优先选择方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Remimazolam is a new alternative drug combining the efficacy and safety advantages of midazolam and propofol. However, studies comparing remimazolam with midazolam in diagnostic upper gastrointestinal endoscopy are insufficient. The purpose of this study was to prove the efficacy and safety of remimazolam in diagnostic upper gastrointestinal endoscopy compared with midazolam. METHODS: This study is a randomized, controlled, multicenter trial. Participants who are to receive diagnostic upper gastrointestinal endoscopy are enrolled and randomly assigned to the remimazolam or midazolam group (control group) at a 1:1 ratio. Remimazolam is given (with an initial 5 mg plus an additional 2.5 mg, maximum 5 times) in the remimazolam group for endoscopic sedation and midazolam is given (with an initial 2 mg plus an additional 1~2 mg, maximum 5 times) in the control group. Flumazenil can be given at the discretion of the investigator. Vital signs, level of consciousness, and adverse events are assessed from the administration of sedatives to the full recovery of consciousness. The primary endpoint is total procedure time, which is defined as the time from the first administration of sedatives to discharge. The secondary endpoints include the success rate of sedation, recovery time, induction time, total endoscopy time, discharge time, sedation time, incidence of hypotension, respiratory depression, tachycardia, bradycardia, participant satisfaction, and paradoxical response incidence. DISCUSSION: The results of this trial are expected to prove the superior efficacy of remimazolam with favorable safety. Based on the results, a sedation method using remimazolam would be applied preferentially for diagnostic upper gastrointestinal endoscopy in clinical practice. TRIAL REGISTRATION: Clinicaltrials.gov NCT05836545. Registered on April 19, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ahn DW, Lee JK, Lee KH, et al. Remimazolam versus midazolam for sedation in diagnostic upper gastrointestinal endoscopy: study protocol for a randomized controlled trial. Trials. 2026. PMID: 41965699. doi:10.1186/s13063-026-09712-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。